Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension

Phase

N/A

Condition

Stress

Vascular Diseases

Circulation Disorders

Treatment

transarterial chemoembolisation

Clinical Study ID

NCT06245798

Tangdu Hospital

Ages > 18
All Genders

Study Summary

Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. HCC patients with CPSH are heterogeneous and treatment allocation remains controversial. The aim of this study was to compare the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in these populations.

Eligibility Criteria

Inclusion

Inclusion Criteria:

HCC patients treated conventional liver resection or transarterial chemoembolisation

Exclusion

Exclusion Criteria:

(1) presence of types III/IV portal vein tumour thrombosis (PVTT), hepatic artery,biliary duct or inferior vena cava invasion; (2) presence of extrahepatic spread (EHS); (3) underwent previous treatments; (4) Eastern Cooperative Oncology GroupPerformance Status (ECOG-PS) >1; (5) diffuse tumor nodules; (6) combined with othertumours or severe cardiac, cerebral, and renal insufficiency; (7) non-Clinicallysignificant portal hypertension（CSPH）, and (8) absence of baseline information

Study Design

transarterial chemoembolisation

January 01, 2023

December 01, 2023

Connect with a study center

Tangdu hospital
Xian, Shaanxi 710000
China
Site Not Available
Xijing hospital
Xian, Shaanxi 710000
China
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.